Pharmacologic inhibition of Gnaq with the compound FR900359 and of Met signaling with Capmatinib abrogated growth of HCmel12 melanoma cells, indicating that the activity of both pathways was required for cell proliferation (Fig. 4a). The gene discussed is GNAQ; the disease is melanoma.